Iaso Bio Enters into CAR-T Therapy Licensing Agreement with Korea's GC Cell for Fucaso® (Elranatamab) in Multiple Myeloma

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

October 29, 2025, IASO BioAnnouncementHas signed a cooperation agreement with South Korea's GC Cell company to jointly promote the CAR-T cell therapy product, Focuxin.^®(IASO Bio's Idecabtagene Vicleucel Injection) Enters the South Korean Market, for the treatment of multiple myeloma. This collaboration aims to provide new treatment options for patients with multiple myeloma in South Korea; GC Cell plans to progressively advance the registration and commercialization process of Focuxin® in South Korea.

Signing Ceremony Group Photo: GC Cell Co-CEOSungyong Won(Left) and Zhang Jinhua, Founder, Chairman, and CEO of IASO Bio (Right)

Multiple Myeloma: A Hard-to-Cure Blood Cancer with High Recurrence Risk, Common Among the Elderly

Fokosu^®It is a CAR-T cell therapy independently developed by IASO Bio, targeting BCMA (B-cell maturation antigen).Approved for marketing by the China National Medical Products Administration in June 2023. By implementing a competitive pricing strategy in South Korea, this innovative therapy is expected to significantly improve patient access locally.

To Promote Fokasol^®Entering the South Korean market, GC Cell helped the therapy obtain orphan drug designation from South Korea’s Ministry of Food and Drug Safety (MFDS) in July this year. In August, Forcused...^®Further designated as a "Fast Track Advanced Therapy Medicinal Product" by South Korean regulatory authorities, accelerating the review and development process. Relying on a stable supply chain, GC CellCommitted to ensuring that patients can access this therapy in a more timely and accessible manner.

Source: IASO Bio